^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-23 inhibitor

    Associations

    News

    Trials
    21h
    Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management. (PubMed, Curr Opin Pharmacol)
    Clinical trials of IL-23p19 inhibitors-such as risankizumab, mirikizumab, and guselkumab-have shown promising results in patients with moderate-to-severe Crohn's disease and ulcerative colitis, with improvements in clinical and endoscopic outcomes and favorable safety profiles. With regulatory approvals expanding in both the United States and Europe, IL-23 inhibitors are now firmly established as a part of the IBD treatment landscape. Looking ahead, efforts are underway to identify biomarkers of response and to explore oral IL-23 inhibitors, with the goal of advancing more personalized and accessible care.
    Review • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL23A (Interleukin 23 Subunit Alpha)
    10d
    Efficacy of Guselkumab in Treating Hailey Hailey Disease (clinicaltrials.gov)
    P2, N=10, Recruiting, Yale University | Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    13d
    EMERGE: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, University of California, San Diego
    New trial
    20d
    Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE). (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, University of Calgary
    New trial
    20d
    Tilrdakizumab Almirall (clinicaltrials.gov)
    P=N/A, N=3, Active, not recruiting, University Hospital Schleswig-Holstein
    New trial
    |
    Ilumya (tildrakizumab-asmn)
    23d
    GUSTO-UK: A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK) (clinicaltrials.gov)
    P=N/A, N=220, Not yet recruiting, Janssen-Cilag Ltd.
    New trial • HEOR • Real-world evidence
    1m
    GURU: A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    1m
    A Prospective, Observational, Multicenter Study Evaluating Endoscopic Healing in Small Intestinal Crohn’s Disease Treated with Guselkumab (ChiCTR2500110828)
    P4, N=50, Not yet recruiting, The Sixth Affiliated Hospital, Sun Yat-sen University; The Sixth Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    2ms
    A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    2ms
    GURU: A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Janssen Research & Development, LLC
    New trial • Real-world evidence
    2ms
    A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov)
    P3, N=38, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    2ms
    APEX: A Study of Guselkumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov)
    P3, N=1054, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2030 --> May 2028
    Trial completion date
    |
    CRP (C-reactive protein)